Kenneth H. Kraemer received his M.D. degree from Tufts Medical School and is Board Certified in Dermatology and in Internal Medicine. He has a long-standing interest in human cancer-prone genetic diseases and DNA repair. His studies focus on molecular, cellular and clinical features of diseases including xeroderma pigmentosum and familial melanoma. He is a member of the American Society for Clinical Investigation and has received awards from the Society for Investigative Dermatology and the U.S. Public Health Service. Dr. Kraemer is co-organizer of the NIH DNA Repair Interest Group.
Human cancer prone genetic diseases are being studied to identify groups
of people with an increased susceptibility to environmental agents. Present
emphasis is on the skin cancer-prone disease, xeroderma pigmentosum (XP)
and on dysplastic nevus syndrome (DNS) of familial melanoma. We are attempting
to: 1) understand the molecular basis of the cellular hypersensitivity
of these diseases, 2) correlate cellular hypersensitivity with clinical
abnormalities, 3) determine the degree of genetic heterogeneity within
such groups, and 4) explore methods of cancer prevention.
We developed plasmid assays to measure DNA repair and mutagenesis at the molecular level in human cells. We found that introduction of cloned DNA repair genes substantially corrected the UV mutagenic defect in XP-D and XP-A cells. We are currently identifying mutations in the DNA repair genes of XP patients and attempting to correlate the molecular defects with their clinical features. Studies of lymphoblastoid cells from normal donors showed increased plasmid UV mutability with increasing donor age suggesting that aging is associated with decreasing ability to repair DNA damage. Lymphoblastoid cell lines from DNS patients with melanoma were found to have abnormally elevated mutability of UV-treated plasmids, a possible cellular marker for this genetic disorder.
Clinical studies of carcinogenesis and chemporevention: Chemoprevention of skin cancer in XP with oral 13-cis retinoic acid (RA) was studied. High dose (2 mg/kg/da) 13-cis RA was effective in preventing skin cancers but very toxic, and low dose (0.5 mg/kg/da) drug gave variable response in different patients ranging from almost complete tumor prevention to no beneficial effect. Despite extensive sun protection, XP patients had normal levels of serum vitamin D indicating an adequate dietary intake of vitamin D. Therapeutic injection of intralesional interferon resulted in marked clearing of multiple melanoma in-situ lesions in one XP patient. The anatomic location of skin cancers in XP patients indicates that although UV exposure causes both melanoma and non-melanoma cancer, the mechanism of skin cancer induction is different for each type of cancer.